Targeting MET in cancer: rationale and progress

E Gherardi, W Birchmeier, C Birchmeier… - Nature reviews …, 2012 - nature.com
Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of
cancer. Genetic and biochemical data have demonstrated that the growth and motility factor …

The molecular biology of head and neck cancer

CR Leemans, BJM Braakhuis, RH Brakenhoff - Nature reviews cancer, 2011 - nature.com
Head and neck squamous cell carcinomas (HNSCCs) are caused by tobacco and alcohol
consumption and by infection with high-risk types of human papillomavirus (HPV). Tumours …

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and …

JJ Cui, M Tran-Dubé, H Shen, M Nambu… - Journal of medicinal …, 2011 - ACS Publications
Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor
tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal …

Targeting adaptive glioblastoma: an overview of proliferation and invasion

Q Xie, S Mittal, ME Berens - Neuro-oncology, 2014 - academic.oup.com
Glioblastoma is one of the most devastating cancers, in which tumor cell infiltration into
surrounding normal brain tissue confounds clinical management. This review describes …

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

JP Eder, GF Vande Woude, SA Boerner… - Clinical Cancer …, 2009 - AACR
A wide variety of human malignancies exhibit sustained c-Met stimulation, overexpression,
or mutation, including carcinomas of the breast, liver, lung, ovary, kidney, and thyroid …

MET: a promising anticancer therapeutic target

S Peters, AA Adjei - Nature reviews Clinical oncology, 2012 - nature.com
The MET pathway is dysregulated in many human cancers and promotes tumour growth,
invasion and dissemination. Abnormalities in MET signalling have been reported to …

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

PA Jänne, N Gray, J Settleman - Nature reviews Drug discovery, 2009 - nature.com
Selective small-molecule kinase inhibitors have emerged over the past decade as an
important class of anti-cancer agents, and have demonstrated impressive clinical efficacy in …

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

TR Webb, J Slavish, RE George, AT Look… - Expert review of …, 2009 - Taylor & Francis
Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor
superfamily, was initially identified in constitutively activated oncogenic fusion forms–the …

[HTML][HTML] Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies

T Rager, A Eckburg, M Patel, R Qiu, S Gantiwala… - Cancers, 2022 - mdpi.com
Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …

Decorin is a novel antagonistic ligand of the Met receptor

S Goldoni, A Humphries, A Nyström, S Sattar… - Journal of Cell …, 2009 - rupress.org
Decorin, a member of the small leucine-rich proteoglycan gene family, impedes tumor cell
growth by down-regulating the epidermal growth factor receptor. Decorin has a complex …